Centre Eyes Essential Commodities Act for Bulk Drugs — Who Gets Hurt, Who Quietly Wins

Centre Eyes Essential Commodities Act for Bulk Drugs — Who Gets Hurt, Who Quietly Wins

The government is reportedly considering invoking the Essential Commodities Act to regulate prices of bulk drugs — the raw active pharmaceutical ingredients (APIs) that go into every medicine. The market's instinct will be to sell pharma stocks broadly. But the real story is more nuanced: this policy would create clear losers among pure-play API manufacturers and quiet winners among formulation companies that buy those same APIs as raw materials.

What's happening

Reports indicate the Centre is exploring the use of the Essential Commodities Act to bring bulk drug prices under regulatory control. Unlike the existing Drug Price Control Order (DPCO), which primarily regulates retail prices of finished formulations, this move would target upstream pricing — the cost of active pharmaceutical ingredients before they reach the consumer.

India's dependence on imported APIs (particularly from China) has been a long-standing policy concern, but domestic API manufacturers have benefited from pricing freedom. That freedom may now face limits.

The companies directly in the crosshairs

Divi's Laboratories (DIVISLAB) is the most exposed large-cap name. As a pure-play API and custom synthesis manufacturer with no meaningful formulation business, any ceiling on bulk drug pricing hits their core revenue. Per their Q3 FY25 quarterly results, Divi's earned a consolidated total income of ₹2,401 crores for the quarter, up 23% from ₹1,950 crores in Q3 FY24, with profit before tax at ₹726 crores versus ₹489 crores a year ago. The company has been riding a strong recovery cycle — price controls could cap that trajectory just as momentum builds. Solara Active Pharma (SOLARA) is another pure API/CRAMS player that would feel direct pressure. Per their Q3 FY25 results, EBITDA margins reached 19.6%, up 180 basis points sequentially, with the company maintaining full-year FY25 EBITDA guidance of ₹2,300–2,600 million. Solara recently announced plans to carve out its CRAMS and polymer business into an independent company — a strategic move that could be complicated by a shifting regulatory landscape on pricing. Neuland Laboratories (NEULANDLAB) focuses on niche, complex-chemistry APIs and custom manufacturing solutions (CMS). The company has developed over 300 processes and 75 APIs with 903+ regulatory filings globally. Their strategy of moving toward higher-value, specialty APIs may offer some insulation — price controls tend to bite hardest on commodity molecules — but the overhang would weigh on sentiment.

The mixed cases

Sun Pharmaceutical Industries (SUNPHARMA) straddles both sides. Per their Q3 FY25 quarterly results, external API sales were ₹5,678 million, growing 21.8% over Q3 last year, with nine-month API sales at ₹15,962 million. However, API is a small fraction of Sun Pharma's total business — India formulation sales alone were ₹43,004 million in Q3FY25, growing 13.8%. As India's No. 1 pharma company with 8.2% market share, Sun Pharma is far more a buyer of APIs than a seller. Lower input costs could actually help margins on their massive formulations business. Aurobindo Pharma (AUROPHARMA) similarly has both API and formulation exposure. Per their Q3 FY23 quarterly results, the API business stood at ₹954.6 crores, contributing 14.9% to consolidated revenues, while formulations made up the remaining 85%. Aurobindo's integrated model — making APIs primarily for its own formulations — means price controls on APIs would reduce a cost line as much as a revenue line.

The quiet winners

Cipla (CIPLA) is perhaps the most interesting second-order beneficiary. Cipla is primarily a formulation company and has been fighting DPCO-related litigation for years — per their quarterly filings, the company has ongoing cases before the Bombay High Court regarding the inclusion of certain drugs under price control, with a ₹175 crore deposit already made to NPPA. Lower bulk drug input costs would directly improve margins on their large India formulation business, while their existing regulatory battles relate to finished drug pricing, not API pricing. Gland Pharma (GLAND) manufactures injectable formulations — a segment where API is a key input cost. Per their Q3 FY25 quarterly results, Gland posted gross margins of 67% and EBITDA margins of 26% on revenue of ₹13,841 million. If their API procurement costs decline due to regulated pricing, those already-strong margins could expand further, particularly as the company focuses on its CDMO (contract development and manufacturing) growth strategy.

What retail investors should do

Don't panic-sell the entire pharma sector. This policy, if implemented, creates a clear divide: pure-play API manufacturers like Divi's Labs, Solara, and Neuland Labs face genuine pricing risk. But integrated and formulation-heavy companies like Sun Pharma, Cipla, and Gland Pharma could actually see their input costs decline, expanding margins on finished drugs. Watch for specifics on which molecules get targeted — commodity APIs face the most risk, while specialty and complex-chemistry APIs may retain pricing flexibility. The smart move is to distinguish between API sellers and API buyers in your portfolio.

Data sourced from company filings on NSE via Xaro.